Women treated with second-generation zotarolimus-eluting resolute stents and everolimus-eluting xience V stents:: insights from the gender-stratified, randomized, controlled TWENTE trial

    loading  Checking for direct PDF access through Ovid



Women are underrepresented in clinical research, and few data are available from randomized head-to-head comparisons of second-generation drug-eluting stents (DES) infemalepatients. Aim of this study was to assess safety and efficacy of two second-generation DES in women. In TWENTE—a prospective, randomized, comparative DES trial—“real-world” patients were stratified for gender before randomization for Resolute or Xience V stents.


Target vessel failure (TVF; cardiac death, target vessel-related myocardial infarction, and clinically indicated target vessel revascularization) after 1 year was the predefined endpoint.


Among 1,391 patients, 382 (27.5%) women were randomized to Resolute (n= 192) and Xience V (n= 190). Baseline and procedural characteristics were similar for females in both study arms, except for smaller vessel and stent diameters in Resolute-treated lesions. After 1 year, TVF (8.9 vs. 8.4%; adjusted odds ratio [OR]: 0.95, 95% confidence interval [CI]: 0.41–2.20,P= 0.91) and a patient-oriented composite endpoint (13.0 vs. 12.1%,P= 0.79) did not differ significantly between women in both arms. Women were older than men (P< 0.01) and had more often diabetes mellitus (26.4 vs. 19.8%,P= 0.01) and hypertension (63.6 vs. 52.5%,P< 0.01), but there was no significant gender difference in TVF (adjusted OR: 1.18, 95% CI: 0.73–1.92,P= 0.50).


This gender-stratified TWENTE trial analysis resulted in no significant difference in safety and efficacy outcomes between Resolute- and Xience V-treated females. © 2013 Wiley Periodicals, Inc.

Related Topics

    loading  Loading Related Articles